LLY ELI LILLY & Co

NYSE lilly.com


$ 931.56 $ 21.36 (2.35 %)    

Wednesday, 05-Nov-2025 15:28:23 EST
QQQ $ 625.52 $ 7.07 (1.14 %)
DIA $ 473.70 $ 2.81 (0.6 %)
SPY $ 679.78 $ 4.74 (0.7 %)
TLT $ 88.97 $ -0.54 (-0.6 %)
GLD $ 366.72 $ 0.27 (0.07 %)
$ 906.86
$ 911.00
$ 931.35 x 101
$ 931.56 x 35
$ 908.54 - $ 955.44
$ 622.41 - $ 931.66
5,911,474
na
815.09B
$ 0.57
$ 44.27
TBD
na
na ($ 0.01)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 10-30-2025 09-30-2025 10-Q
2 08-07-2025 06-30-2025 10-Q
3 05-01-2025 03-31-2025 10-Q
4 02-19-2025 12-31-2024 10-K
5 10-30-2024 09-30-2024 10-Q
6 08-08-2024 06-30-2024 10-Q
7 04-30-2024 03-31-2024 10-Q
8 02-21-2024 12-31-2023 10-K
9 11-02-2023 09-30-2023 10-Q
10 08-08-2023 06-30-2023 10-Q
11 04-27-2023 03-31-2023 10-Q
12 02-22-2023 12-31-2022 10-K
13 11-01-2022 09-30-2022 10-Q
14 08-04-2022 06-30-2022 10-Q
15 04-29-2022 03-31-2022 10-Q
16 02-23-2022 12-31-2021 10-K
17 10-27-2021 09-30-2021 10-Q
18 08-03-2021 06-30-2021 10-Q
19 04-30-2021 03-31-2021 10-Q
20 02-17-2021 12-31-2020 10-K
21 10-28-2020 09-30-2020 10-Q
22 07-31-2020 06-30-2020 10-Q
23 05-01-2020 03-31-2020 10-Q
24 02-19-2020 12-31-2019 10-K
25 10-25-2019 09-30-2019 10-Q
26 08-02-2019 06-30-2019 10-Q
27 05-02-2019 03-31-2019 10-Q
28 02-19-2019 12-31-2018 10-K
29 11-06-2018 09-30-2018 10-Q
30 07-25-2018 06-30-2018 10-Q
31 04-27-2018 03-31-2018 10-Q
32 02-20-2018 12-31-2017 10-K
33 10-27-2017 09-30-2017 10-Q
34 07-28-2017 06-30-2017 10-Q
35 05-01-2017 03-31-2017 10-Q
36 02-21-2017 12-31-2016 10-K
37 10-28-2016 09-30-2016 10-Q
38 07-28-2016 06-30-2016 10-Q
39 04-29-2016 03-31-2016 10-Q
40 02-19-2016 12-31-2015 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 stocks-rebound-eli-lilly-jumps-to-14-month-highs-whats-moving-markets-wednesday

Wall Street bounced back Wednesday after Tuesday's sharp selloff in AI-driven stocks, as investors bought the dip amid soli...

Core News & Articles

https://x.com/jenniferjjacobs/status/1986132394470985850?s=46&t=dtUiyC3dUs5yGRgT9qYHWg

 druckenmillers-viking-trade-just-hit-a-golden-cross--and-a-sweet-36-gain

Stanley Druckenmiller's firm bought Viking Therapeutics stock (VKTX) during Q2 at $25.33. Now up 36%, VKTX shows a Golden C...

 jim-cramer-says-take-a-pass-on-this-tech-stock-wont-go-near-oils

Zoom Communications is a good company, Cramer says. Still, he advises, "take a pass." Plus: Viking Therapeutics, Profra...

 eli-lilly-novo-nordisk-stocks-rise-on-reported-149-obesity-drug-deal-with-white-house

Eli Lilly and Company (NYSE:LLY) shares are trading slightly lower on Tuesday after its previous gains following reports indica...

Core News & Articles

https://endpoints.news/lilly-and-novo-near-white-house-deal-on-obesity-drugs-prices/

 whats-up-with-the-rise-in-eli-lilly-stock-today

Eli Lilly shares are trading higher on Monday. The pharmaceutical giant announced a significant European manufacturing expansion.

 eli-lilly-plans-to-construct-3b-production-site-in-katwijk-netherlands

Eli Lilly and Company (NYSE: LLY) announced today plans to build a new $3 billion manufacturing facility in Katwijk, the Nether...

Core News & Articles

-Reuters

 eli-lilly-seen-in-pole-position-for-growth-analysts-say

Eli Lilly shares rise as Q3 revenue jumps 54% to $17.6 billion, earnings top estimates, and analysts lift price targets on stro...

 cantor-fitzgerald-maintains-overweight-on-eli-lilly-raises-price-target-to-985

Cantor Fitzgerald analyst Carter Gould maintains Eli Lilly (NYSE:LLY) with a Overweight and raises the price target from $92...

 eli-lilly-extends-lead-in-150b-obesity-drug-race-as-novo-pfizer-clash--heres-how-etfs-stand-to-gain

As Eli Lilly, Novo Nordisk, and Pfizer battle for dominance in the obesity-drug market, these ETFs are offering exposure to the...

 meta-tumbles-10-google-marks-historic-rally-whats-moving-markets-thursday

Wall Street saw a cautious tone on Thursday as major tech-heavy indexes edged lower, weighed down by mixed earnings from the me...

 nvidias-5-trillion-milestone-turns-these-ai-etfs-into-hot-trades

Nvidia's $5 trillion valuation record is igniting momentum across semiconductor and AI-themed ETFs as investors chase the n...

 eli-lilly-executive-says-europe-revenue-increased-by-over-100-in-constant-currency-reflecting-strong-uptake-of-mounjaro-on-mounjaro-says-we-have-now-launched-in-55-countries-and-all-major-markets

-Reuters Citing Conf. Call

 mounjaro-and-zepbound-power-eli-lillys-54-revenue-jump-in-q3-hikes-2025-forecast

Eli Lilly reported Q3 revenue of $17.6 billion, beating estimates and raising 2025 guidance as Mounjaro and Zepbound sales surged.

Core News & Articles

GPRK: 28% | Geopark shares are trading higher after Parex Resources submitted a proposal to acquire all outstanding shares of t...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION